Eli Lilly has identified 3D printing as a way to get drugs to specific regions of the gastrointestinal tract, leading it to team up with Triastek to work on the targeted release of molecules in the intestine.

Triastek’s MED 3D printing technology enables it to apply layer upon layer of melted excipients, active pharmaceutical ingredients and blended materials. In doing so, the Chinese biotech could unlock new ways to control drug release. Triastek is applying the technology to its internal pipeline, the two most advanced candidates in which have IND clearance, and using it to support partnered programs.

Lilly sees promise in the technology. The collaboration with Triastek has two parts. Firstly, Lilly will work with its new partner to study the excipient properties and process parameters needed to maintain the stability of the drug throughout formulation development, 3D printing and payload release.  

Follow us:

Share this article:

LinkedIn